Abstract
S-adenosyl-l-methionine (SAMe), a naturally occurring brain metabolite, has previously been found to be effective and tolerated well in parenteral form as a treatment of major depression. To explore the antidepressant potential of oral SAMe, we conducted an open trial in 20 outpatients with major depression, including those with (n = 9) and without (n = 11) prior history of antidepressant nonresponse. The group as a whole significantly improved with oral SAMe: 7 of 11 non-treatment-resistant and 2 of 9 treatment-resistant patients experienced full antidepressant response. Side effects were mild and transient.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adult
-
Clinical Trials as Topic
-
Depressive Disorder / blood
-
Depressive Disorder / psychology
-
Depressive Disorder / therapy*
-
Dexamethasone
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Hydrocortisone / blood
-
Male
-
Middle Aged
-
Psychiatric Status Rating Scales
-
S-Adenosylmethionine / administration & dosage*
-
Single-Blind Method
-
Thyrotropin / blood
-
Thyrotropin-Releasing Hormone
Substances
-
Thyrotropin-Releasing Hormone
-
S-Adenosylmethionine
-
Dexamethasone
-
Thyrotropin
-
Hydrocortisone